Teva's been facing generic competition for lead drug Copaxone since Novartis' Sandoz launched a copy of the multiple sclerosis blockbuster last June. And that competition has started taking its toll, dragging sales below expectations in 2015.
Shire's been somewhat of an M&A machine as of late, making a string of deals that most recently included its largest-ever, Baxalta. But it's an old standby that helped the company beat analyst estimates for Q4.
Pet hospital chain VCA was in a precarious position in the third quarter, missing revenue forecasts despite a beat on earnings. The company found its footing in Q4, though, finishing the year strong with Street-beating numbers thanks to standout performances from its animal hospital and lab businesses.
Catalent Pharma Solutions remained stagnant in its fiscal second quarter, as global currency fluctuations undid baseline growth in its banner businesses.
Some presidential hopefuls have a bone to pick with Big Pharma, with candidates such as Hillary Clinton, Bernie Sanders and Donald Trump railing against drug price increases and calling for reform. But candidates are also picking up checks from the industry this election, collectively raking in almost $1 million in campaign contributions from pharma companies.
Quintiles, the world's largest CRO, is expecting its revenue to jump as much as 8.5% in 2016 on the heels of a record year.
Phibro Animal Health missed expectations in its second fiscal quarter, reporting after the market closed on Feb. 9 that it earned $0.39 a share on $192 million in sales. Sales were up 2% year over year and earnings grew 11%, but analysts had been expecting $198.3 million in sales and EPS of $0.41, according to Thomson Financial Network.
The high-stakes rollout of Sanofi's dengue vaccine, Dengvaxia, is slated this month in the private market, the lead executive for the product said, adding that a tender for 3 million doses is in advanced discussions in the Philippines for a public launch within weeks.
Actelion may have a blockbuster on the decline--but it's also got two new launches that are keeping it in the game. For 2015, the Swiss company reported sales that were in line with analyst expectations and core earnings that beat them. Sales climbed 4% year over year to hit CHF 2.04 billion, while earnings rose to CHF 814 million ($827.24 million), besting predictions of CHF 813 million.
If you expected a catalog of detail on Sanofi's turnaround plans with Tuesday's earnings release, think again.